HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: Moreover, the subgroup analysis was utilized to assess the efficacy among different HDAC inhibitors and efficacy in different PTCL subtypes.<h4>Results</h4>For untreated PTCL, 502 patients in seven studies were involved, and the pooled CR rate was 44% (95% <i>CI</i>, 39-48%).